TY - JOUR
T1 - Pathogenetic mechanisms in chronic myeloproliferative disorders
T2 - Polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia
AU - Tefferi, A.
PY - 1999
Y1 - 1999
N2 - The stem cell origination of the clonal process in chronic myeloproliferative disorders (CMPDs) is well established. In chronic myelogenous leukemia (CML), the primary genetic process has been characterized. However, current information regarding the mechanisms of phenotypic diversity among the CMPD and the downstream effects of the cbromosomal translocation in CML remains inconclusive. In this report, the current understanding regarding erythrocytosis in polycythemia vera (PV), thrombocytosis in essential thrombocythemia (ET), bone marrow fibrosis (BMF) in agnogenic myeloid metaplasia (AMM), and the connection between the genetic alteration and cellular transformation in CML will be discussed.
AB - The stem cell origination of the clonal process in chronic myeloproliferative disorders (CMPDs) is well established. In chronic myelogenous leukemia (CML), the primary genetic process has been characterized. However, current information regarding the mechanisms of phenotypic diversity among the CMPD and the downstream effects of the cbromosomal translocation in CML remains inconclusive. In this report, the current understanding regarding erythrocytosis in polycythemia vera (PV), thrombocytosis in essential thrombocythemia (ET), bone marrow fibrosis (BMF) in agnogenic myeloid metaplasia (AMM), and the connection between the genetic alteration and cellular transformation in CML will be discussed.
UR - http://www.scopus.com/inward/record.url?scp=0032947629&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032947629&partnerID=8YFLogxK
M3 - Review article
C2 - 9930550
AN - SCOPUS:0032947629
SN - 0037-1963
VL - 36
SP - 3
EP - 8
JO - Seminars in Hematology
JF - Seminars in Hematology
IS - SUPPL. 2
ER -